Beyond the headlines: Why we are excited about our pipeline and the future for patients needing effective treatments for infections

Beyond the headlines: Why we are excited about our pipeline and the future for patients needing effective treatments for infections

By: Ankit Mahadevia, MD – CEO of Spero Therapeutics January 9th, 2020 Against a steady drumbeat of alarmist rhetoric in the lay press regarding infectious disease, at Spero we remain focused on developing our first-in-class pipeline of oral agents to treat what we believe to be the two largest infectious disease market opportunities:  complicated urinary tract infections […]

Exciting Independent Review Committee Recommendation Announced Today Based on Positive Interim PK Data from SPR994 ADAPT-PO Phase 3 Clinical Trial

By:  David Melnick, MD – Chief Medical Officer of Spero Therapeutics October 3, 2019 Today we announced that an independent review committee evaluated pharmacokinetic data following enrollment of the first 70 patients in Spero’s ongoing ADAPT-PO pivotal Phase 3 clinical trial of SPR994, Spero’s oral carbapenem product candidate, and recommended that Spero continue the trial […]

SPR994’s Value Proposition: A dive into how SPR994, an oral carbapenem, could benefit patients, payers, and investors

By: Joel Sendek, Chief Financial Officer May 16th, 2019 Spero has an enterprise value that does not reflect what we believe are significant market opportunities for our lead asset, an oral carbapenem SPR994, and our other product candidates. SPR994 is currently in a pivotal Phase 3 trial for the treatment of complicated urinary tract infections (cUTI), […]

Designing the Right Clinical Trial to Yield the Greatest Value

By: David Melnick, MD  and Cristina Larkin  January 7th, 2019 In today’s health care environment, a randomized, well-controlled trial must not only meet the requirements for approval, but just as importantly, it must encourage early physician use and provide payors a justification for payment. Today, we announced positive feedback from our pre-Phase 3 FDA meeting for SPR994 for […]